# Phase 3 Trial to Evaluate the Efficacy and Safety of DKP21102_B Added on to DKP21102_A Compared With DKP21102_A

> **NCT05809687** · PHASE3 · WITHDRAWN · sponsor: **Dongkwang Pharm. Co., Ltd.**

## Conditions studied

- Dyslipidemias

## Interventions

- **DRUG:** DKP21102_C
- **DRUG:** DKP21102_B
- **DRUG:** DKP21102_A

## Key facts

- **NCT ID:** NCT05809687
- **Lead sponsor:** Dongkwang Pharm. Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2025-01-01
- **Primary completion:** 2026-12-01
- **Final completion:** 2027-12-01
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** The clinical trial was withdrawn due to a commercial decision.
- **Last updated:** 2024-10-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05809687

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05809687, "Phase 3 Trial to Evaluate the Efficacy and Safety of DKP21102_B Added on to DKP21102_A Compared With DKP21102_A". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05809687. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*